PHAT
Phathom Pharmaceuticals Inc

2,387
Mkt Cap
$1.2B
Volume
583,263.00
52W High
$18.31
52W Low
$2.21
PE Ratio
-4.35
PHAT Fundamentals
Price
$16.59
Prev Close
$16.92
Open
$16.82
50D MA
$14.84
Beta
1.21
Avg. Volume
865,294.74
EPS (Annual)
-$5.29
P/B
-2.79
Rev/Employee
$129,395.79
Loading...
Loading...
News
all
press releases
Simplify Asset Management Inc. Reduces Position in Phathom Pharmaceuticals, Inc. $PHAT
Simplify Asset Management Inc. reduced its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 38.3% during the third quarter, according to its most recent filing with the...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Notable Monday Option Activity: PHAT, WHR, QBTS
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Phathom Pharmaceuticals Inc (Symbol: PHAT), where a total of 5,492 contracts have traded...
Nasdaq News: Markets·10d ago
News Placeholder
Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT)
Raymond James Financial began coverage on Phathom Pharmaceuticals in a research report on Thursday. They issued a "strong-buy" rating and a $28.00 target price on the stock...
MarketBeat·18d ago
News Placeholder
Frazier Life Sciences Management L.P. Purchases 2,357,210 Shares of Phathom Pharmaceuticals, Inc. $PHAT
Frazier Life Sciences Management L.P. lifted its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 23.3% in the 2nd quarter, according to the company in its most...
MarketBeat·18d ago
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month High - What's Next?
Phathom Pharmaceuticals (NASDAQ:PHAT) Hits New 52-Week High - Here's What Happened...
MarketBeat·19d ago
News Placeholder
683 Capital Management LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. $PHAT
683 Capital Management LLC grew its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 45.7% during the 2nd quarter, according to the company in its most recent disclosure with...
MarketBeat·19d ago
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays
Barclays raised Phathom Pharmaceuticals to a "hold" rating in a research note on Monday...
MarketBeat·21d ago
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year High - What's Next?
Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year High - Still a Buy...
MarketBeat·1mo ago
News Placeholder
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat...
MarketBeat·2mo ago
News Placeholder
Simplify Asset Management Inc. Sells 160,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT
Simplify Asset Management Inc. decreased its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 23.5% in the 2nd quarter, according to its most recent 13F filing with...
MarketBeat·2mo ago
<
1
2
...
>

Latest PHAT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.